**Appendix Four – Sacubitril Valsartan for treating symptomatic HFrEF**

**Sacubitril Valsartan for symptomatic chronic HFrEF**

**Screening/Eligibility checklist; with initiation and up titration dose**

**recommendations.**

*The purpose of this document is to assist in clinic decision making, initial dosing, up*

 *titration schedule and can be used as an audit record.*

|  |
| --- |
| **Patient Details – Complete or affix with patient label** |
| Surname: |
| Forename: |
| Address: |
| Postcode: |
| Hospital Number: |
| DOB: Male/Female |

|  |  |  |
| --- | --- | --- |
| **NICE Recommendations for Sacubitril Valsartan (TA388 2016)** | **Yes** | **No** |
| *Tick as appropriate – all four criteria must be met* |
| 1. Left ventricular ejection fraction ≤ 35%
 |  |  |
| 1. NYHA Class II-IV
 |  |  |
| 1. Currently taking a stable dose of ACEi or ARB
 |  |  |
| 1. No contraindications to treatment (See BNF or SmPC)
 |  |  |

|  |
| --- |
| **Baseline Monitoring** |
| Heart Rate |  | EF (%) |  | Cr |  | eGFR |  |
| BP |  | NYHA Class |  | K |  | Hb |  |
| ALT |  | ALP |  | Bilirubin |  | NTproBNP |  |

|  |  |
| --- | --- |
| **Details of Sacubitril Valsartan dosing initiation schedule** | **Tick** |
| Standard initiation dose: 49/51mg twice daily. |  |
| Reduced initiation dose: 24/26mg twice daily if any of the following present:* Systolic BP ≤ 100-110 mmHg
* eGFR 30-60ml.min/1.73m2
* Moderate hepatic impairment (Child-Pugh B) or AST/ALP more than two times the upper limit of normal range
* Taking low dose ACEi or ARB
 |  |
| Supplied by hospital pharmacy. 56 tablets (28 days therapy) will be the usual initiating quantity prescribed |

|  |
| --- |
| **Ensure that ACEi or ARB is discontinued prior to initiation** |
| If on ACEi – STOP for at least 36 hours prior to starting Sacubitril Valsartan, due to risk of angioedema |
| If on ARB – STOP and replace next dose with Sacubitril Valsartan |
| Date ACEi/ARB Stopped: |  | Date Sacubitril Valsartan Started: |  |

|  |  |  |
| --- | --- | --- |
| **Patient Information** | **Yes** | **No** |
| The patient is aware of the indication, benefits and risks of Sacubitril Valsartan, that it replaces any ACEi or ARB and agrees to therapy. |  |  |
| **Up-Titration Monitoring in clinic at after 4 weeks of therapy** |
| Heart Rate |  | NYHA Class |  | Cr |  | eGFR |  |
| BP |  | K |  | Hb |  | NTproBNP |  |
| **Documentation of Adverse Events** |
|  | **Tick** |
| Yellow Card report submitted |  |

|  |  |
| --- | --- |
| **Details of Sacubitril Valsartan up-titration schedule** | **Tick** |
| Up-titration dose: 49/51mg twice daily. |  |
| Up-titration dose: 97/103mmHg twice daily |  |
| Supplied by hospital pharmacy. 56 tablets (28 days therapy) will be the usual initiating quantity prescribed |

|  |
| --- |
| **Up-Titration Monitoring in clinic after 4 weeks of therapy (if required)** |
| Heart Rate |  | NYHA Class |  | Cr |  | eGFR |  |
| BP |  | K |  | Hb |  | NTproBNP |  |
| **Documentation of Adverse Events** |
|  | **Tick** |
| Yellow Card report submitted |  |

|  |  |
| --- | --- |
| **Details of Sacubitril Valsartan up-titration schedule** | **Tick** |
| Up-titration dose: 97/103mmHg twice daily |  |
| Supplied by hospital pharmacy. 56 tablets (28 days therapy) will be the usual initiating quantity prescribed |

|  |  |
| --- | --- |
| **Once Optimisation achieved** |  |
| Stable dose of Sacubitril Valsartan achieved: |  |
| Communication with GP regarding dose: |  |